Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-121109
Filing Date
2018-04-18
Accepted
2018-04-18 16:44:56
Documents
6
Period of Report
2018-05-30
Effectiveness Date
2018-04-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A d556965ddef14a.htm DEF 14A 623337
2 GRAPHIC g556965g21w10.jpg GRAPHIC 33374
3 GRAPHIC g556965g38l86.jpg GRAPHIC 23213
4 GRAPHIC g556965g47k82.jpg GRAPHIC 25755
5 GRAPHIC g556965g54t09.jpg GRAPHIC 22635
6 GRAPHIC g556965g77a13.jpg GRAPHIC 23954
  Complete submission text file 0001193125-18-121109.txt   802026
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37923 | Film No.: 18761583
SIC: 2836 Biological Products, (No Diagnostic Substances)